- Leap Therapeutics (LPTX -3.9%) will collaborate with the European Organisation for Research and Treatment of Cancer (EORTC) on a clinical study investigating certain combination regimens that include lead product candidate DKN-01 in advanced cancers.
- The EORTC-sponsored trial will assess the combination of DKN-01 and Roche's TECENTRIQ (atezolizumab), with or without the chemo agent paclitaxel, in patients with advanced esophagogastric cancers and DKN-01 + TECENTRIQ in patients with advanced biliary tract cancers. Roche will supply product. Enrollment should commence in 2018.
- DKN-01 is a humanized IgG4 monoclonal antibody that binds to Dickkopf-1 (DKK1), a protein associated with a poor prognosis in a range of cancers. Specifically, it inhibits a pathway called canonical Wnt/Beta-catenin which plays a key role in embryonic development, cell proliferation and differentiation.
- Investors appear unimpressed. The stock is down on 40% higher volume, albeit on turnover of only 24k shares.
- Previously: Leap Therapeutics to explore the potential of DKN-01/Keytruda combo in treatment -resistant esophagogastric cancers; shares ahead 5% (June 21)
- Now read: 2 Game-Changers In Therapeutic Proteins: Protalix's ProCellEx And Prometic's PPPS
Original article